Literature DB >> 16863006

Comparison of Dynabeads and Capcellia methods with FACScount for the estimation of CD4 T-lymphocyte levels in HIV/AIDS patients in Lagos, Nigeria.

E O Idigbe1, R A Audu, C T Oparaugo, D Onwujekwe, C C Onubogu, J Adedoyin, A G Mafe, R Okoye, J I Onyewuche, E O Funso-Adebayo, E Meshack.   

Abstract

OBJECTIVE: To compare the efficacy of the Capcellia assay and the Dynabeads technique against the FACScount technique in the estimation of CD4 T-lymphocytes within a Nigerian setting.
DESIGN: Prospective study.
SETTING: Urban area in Nigeria.
SUBJECTS: Ninety seven subjects (51 HIV seronegative and 46 HIV seropositive adults) seen in the blood banks and two out patient clinics in Lagos within the study period. MAIN OUTCOME MEASURES: Dynadeads technique with a higher correlation coefficient is a feasible alternative to the FACScount method.
RESULTS: There was an overall correlation coefficient of r = 0.75 for CD4 cell counts as determined by the Dynabeads technique in comparison with the FACScount method. Also, an overall correlation coefficient of r = 0.17 for CD4 cell counts as determined by the Capcellia technique against the FACScount method.
CONCLUSION: Dynabeads technique is simple to carry out and cheaper in terms of demand for human expertise and infrastructural requirements than the FACScounts. Therefore, it was recommended for use in the laboratory for monitoring of ARV therapy in Nigeria and any other resource poor

Entities:  

Mesh:

Year:  2006        PMID: 16863006     DOI: 10.4314/eamj.v83i4.9424

Source DB:  PubMed          Journal:  East Afr Med J        ISSN: 0012-835X


  2 in total

1.  Performance evaluation of the MBio Diagnostics point-of-care CD4 counter.

Authors:  Cathy Logan; Monique Givens; Jeffrey T Ives; Marie Delaney; Michael J Lochhead; Robert T Schooley; Constance A Benson
Journal:  J Immunol Methods       Date:  2012-10-11       Impact factor: 2.303

Review 2.  CD4 enumeration technologies: a systematic review of test performance for determining eligibility for antiretroviral therapy.

Authors:  Rosanna W Peeling; Kimberly A Sollis; Sarah Glover; Suzanne M Crowe; Alan L Landay; Ben Cheng; David Barnett; Thomas N Denny; Thomas J Spira; Wendy S Stevens; Siobhan Crowley; Shaffiq Essajee; Marco Vitoria; Nathan Ford
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.